RA Capital Management L.P. Makes New Investment in Sutro Biopharma, Inc. $STRO

by · The Cerbat Gem

RA Capital Management L.P. acquired a new position in Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) in the 1st quarter, HoldingsChannel reports. The fund acquired 4,434,637 shares of the company’s stock, valued at approximately $2,885,000. RA Capital Management L.P. owned 0.05% of Sutro Biopharma as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its stake in Sutro Biopharma by 15.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,136,457 shares of the company’s stock worth $2,091,000 after purchasing an additional 156,139 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in Sutro Biopharma by 100.0% in the first quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company’s stock worth $33,000 after purchasing an additional 25,000 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Sutro Biopharma by 82.7% in the fourth quarter. BNP Paribas Financial Markets now owns 150,758 shares of the company’s stock worth $277,000 after purchasing an additional 68,234 shares during the last quarter. Invesco Ltd. lifted its stake in Sutro Biopharma by 54.2% in the fourth quarter. Invesco Ltd. now owns 38,749 shares of the company’s stock worth $71,000 after purchasing an additional 13,620 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Sutro Biopharma during the fourth quarter valued at approximately $4,729,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

Sutro Biopharma stock opened at $0.86 on Tuesday. The firm has a 50 day moving average price of $0.81 and a 200 day moving average price of $0.91. The company has a market capitalization of $72.66 million, a PE ratio of -0.34 and a beta of 1.57. Sutro Biopharma, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $4.80.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.25. The business had revenue of $63.74 million during the quarter, compared to the consensus estimate of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. As a group, equities research analysts forecast that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Wall Street Zen downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Friday, August 22nd. Wells Fargo & Company dropped their price objective on shares of Sutro Biopharma from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 12th. Piper Sandler upgraded shares of Sutro Biopharma from a “neutral” rating to an “overweight” rating and set a $2.00 target price for the company in a research report on Monday, June 16th. Finally, Bank of America decreased their price objective on shares of Sutro Biopharma from $1.00 to $0.80 and set an “underperform” rating for the company in a research report on Monday, May 19th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sutro Biopharma has a consensus rating of “Hold” and an average target price of $4.47.

Read Our Latest Stock Report on Sutro Biopharma

About Sutro Biopharma

(Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Featured Articles

Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report).